sulforaphane

aryl hydrocarbon receptor-dependent cytochrome P-450 (phase I) induction

no effect

induces phase II enzymes selectively without the induction of aryl hydrocarbon receptor-dependent cytochromes P-450 (phase I enzymes)

PMID:1549603 · one of two readings recorded this

inducer potency of sulforaphane versus synthetic analogues

increases

Sulforaphane is the most potent inducer, and the presence of oxygen on sulfur enhances potency

PMID:1549603 · one of two readings recorded this

quinone reductase and glutathione transferase activities

increases

Sulforaphane and its sulfide and sulfone analogues induced both quinone reductase and glutathione transferase activities in several mouse tissues

PMID:1549603 · one of two readings recorded this

quinone reductase induction (isolation of sulforaphane from broccoli)

increases

we have isolated and identified (-)-1-isothiocyanato-(4R)-(methylsulfinyl)butane [CH3-SO-(CH2)4-NCS, sulforaphane] as a major and very potent phase II enzyme inducer in SAGA broccoli (Brassica oleracea italica)

PMID:1549603 · one of two readings recorded this

efficacy in reducing inflammation / neuroprotection after spinal cord injury, compared with interleukin-10

Not recorded as a finding: the comparison was against another active treatment

The meta-analysis revealed that exogenous IL-10 was more effective in comparison with the mentioned herbal extracts.

PMID:24969510 · both readings recorded this

inflammation reduction

decreases

Tetramethylpyrazine has an acceptable influence in reducing inflammation through the up-regulation of IL-10

PMID:24969510 · one of two readings recorded this

neuroprotection / reduction of inflammation after spinal cord injury

decreases

The meta-analysis revealed that exogenous IL-10 was more effective in comparison with the mentioned herbal extracts

PMID:24969510 · one of two readings recorded this

neuroprotection / reduction of inflammation after spinal cord injury

decreases

Outcomes of sulforaphane and tanshinone IIA administration are acceptable but still weaker than IL-10

PMID:24969510 · one of two readings recorded this

baseline cruciferous vegetable intake vs change in WHO grade

decreases

dietary intake of cruciferous vegetables at the start of the study (T0) was significantly inversely correlated with the change in WHO grade over the 12-mo study period

PMID:30982861 · one of two readings recorded this

expression of NRF2-regulated genes, start vs end of intervention

no effect, p = 0.1

There was no evidence of a change in expression of any NRF2-regulated genes between the start and end of the dietary intervention (Benjamini–Hochberg FDR-adjusted P value <0.1)

PMID:30982861 · one of two readings recorded this

genes changed over time, FDR-adjusted P <0.05

modulates

<0.05 | 7 (4↑, 3↓) | 0 | 0

PMID:30982861 · one of two readings recorded this

genes changed over time, FDR-adjusted P <0.05

no effect

<0.05 | 7 (4↑, 3↓) | 0 | 0

PMID:30982861 · one of two readings recorded this

genes changed over time, FDR-adjusted P <0.05

no effect

<0.05 | 7 (4↑, 3↓) | 0 | 0

PMID:30982861 · one of two readings recorded this

genes changed over time, FDR-adjusted P <0.1

modulates

<0.1 | 96 (58↑, 38↓) | 0 | 0

PMID:30982861 · one of two readings recorded this

genes changed over time, FDR-adjusted P <0.1

no effect

<0.1 | 96 (58↑, 38↓) | 0 | 0

PMID:30982861 · one of two readings recorded this

genes changed over time, FDR-adjusted P <0.1

no effect

<0.1 | 96 (58↑, 38↓) | 0 | 0

PMID:30982861 · one of two readings recorded this

genes changed over time, unadjusted P <0.001

modulates

<0.001 | 154 (82↑, 72↓) | 26 (20↑, 6↓) | 12 (8↑, 4↓)

PMID:30982861 · one of two readings recorded this

genes changed over time, unadjusted P <0.001

modulates

<0.001 | 154 (82↑, 72↓) | 26 (20↑, 6↓) | 12 (8↑, 4↓)

PMID:30982861 · one of two readings recorded this

genes changed over time, unadjusted P <0.001

modulates

<0.001 | 154 (82↑, 72↓) | 26 (20↑, 6↓) | 12 (8↑, 4↓)

PMID:30982861 · one of two readings recorded this

genes changed over time, unadjusted P <0.01

modulates

<0.01 | 980 (520↑, 460↓) | 331 (224↑, 107↓) | 83 (46↑, 37↓)

PMID:30982861 · one of two readings recorded this

genes changed over time, unadjusted P <0.01

modulates

<0.01 | 980 (520↑, 460↓) | 331 (224↑, 107↓) | 83 (46↑, 37↓)

PMID:30982861 · one of two readings recorded this

genes changed over time, unadjusted P <0.01

modulates

<0.01 | 980 (520↑, 460↓) | 331 (224↑, 107↓) | 83 (46↑, 37↓)

PMID:30982861 · one of two readings recorded this

genes changed over time, unadjusted P <0.05

modulates

<0.05 | 2796 (1460↑, 1336↓) | 1359 (783↑, 576↓) | 502 (277↑, 225↓)

PMID:30982861 · one of two readings recorded this

genes changed over time, unadjusted P <0.05

modulates

<0.05 | 2796 (1460↑, 1336↓) | 1359 (783↑, 576↓) | 502 (277↑, 225↓)

PMID:30982861 · one of two readings recorded this

genes changed over time, unadjusted P <0.05

modulates

<0.05 | 2796 (1460↑, 1336↓) | 1359 (783↑, 576↓) | 502 (277↑, 225↓)

PMID:30982861 · one of two readings recorded this

genes significantly changed over 12 mo, FDR-adjusted P < 0.5

no effect, p = 0.5

men who consumed the highest amount of glucoraphanin (soup Z) had only 1 gene that significantly changed in expression over the 12-mo period (FDR-adjusted P < 0.5)

PMID:30982861 · one of two readings recorded this

GSEA androgen response, change over time

decreases

Androgen response | 93 | −2.13 3 | 0 3 | −1.62 3 | 0.014 3 | −1.45 | 0.055

PMID:30982861 · one of two readings recorded this

GSEA androgen response, change over time

decreases, p = 0.014

Androgen response | 93 | −2.13 3 | 0 3 | −1.62 3 | 0.014 3 | −1.45 | 0.055

PMID:30982861 · one of two readings recorded this

GSEA androgen response, change over time

no effect, p = 0.055

Androgen response | 93 | −2.13 3 | 0 3 | −1.62 3 | 0.014 3 | −1.45 | 0.055

PMID:30982861 · one of two readings recorded this

GSEA angiogenesis, change over time

increases, p = 0.001

Angiogenesis | 30 | 1.89 3 | 0.001 3 | 2.06 3 | 0 3 | −1.61 3 | 0.016 3

PMID:30982861 · one of two readings recorded this

GSEA angiogenesis, change over time

increases

Angiogenesis | 30 | 1.89 3 | 0.001 3 | 2.06 3 | 0 3 | −1.61 3 | 0.016 3

PMID:30982861 · one of two readings recorded this

GSEA angiogenesis, change over time

decreases, p = 0.016

Angiogenesis | 30 | 1.89 3 | 0.001 3 | 2.06 3 | 0 3 | −1.61 3 | 0.016 3

PMID:30982861 · one of two readings recorded this

GSEA apoptosis, change over time

increases, p = 0.002

Apoptosis | 140 | 1.71 3 | 0.002 3 | 1.99 3 | 0 3 | −1.19 | 0.259

PMID:30982861 · one of two readings recorded this

GSEA apoptosis, change over time

increases

Apoptosis | 140 | 1.71 3 | 0.002 3 | 1.99 3 | 0 3 | −1.19 | 0.259

PMID:30982861 · one of two readings recorded this

GSEA apoptosis, change over time

no effect, p = 0.259

Apoptosis | 140 | 1.71 3 | 0.002 3 | 1.99 3 | 0 3 | −1.19 | 0.259

PMID:30982861 · one of two readings recorded this

GSEA epithelial-mesenchymal transition, change over time

increases

Epithelial–mesenchymal transition | 176 | 2.70 3 | 0 3 | 2.30 3 | 0 3 | −1.03 | 0.558

PMID:30982861 · one of two readings recorded this

GSEA epithelial-mesenchymal transition, change over time

increases

Epithelial–mesenchymal transition | 176 | 2.70 3 | 0 3 | 2.30 3 | 0 3 | −1.03 | 0.558

PMID:30982861 · one of two readings recorded this

GSEA epithelial-mesenchymal transition, change over time

no effect, p = 0.558

Epithelial–mesenchymal transition | 176 | 2.70 3 | 0 3 | 2.30 3 | 0 3 | −1.03 | 0.558

PMID:30982861 · one of two readings recorded this

GSEA inflammatory response, change over time

increases

Inflammatory response | 152 | 1.95 3 | 0 3 | 2.36 3 | 0 3 | 0.95 | 1

PMID:30982861 · one of two readings recorded this

GSEA inflammatory response, change over time

increases

Inflammatory response | 152 | 1.95 3 | 0 3 | 2.36 3 | 0 3 | 0.95 | 1

PMID:30982861 · one of two readings recorded this

GSEA inflammatory response, change over time

no effect, p = 1

Inflammatory response | 152 | 1.95 3 | 0 3 | 2.36 3 | 0 3 | 0.95 | 1

PMID:30982861 · one of two readings recorded this

GSEA reactive oxygen species, change over time

no effect, p = 0.302

Reactive oxygen species | 42 | −1.14 | 0.302 | 1.32 | 0.077 | −1.63 3 | 0.014 3

PMID:30982861 · one of two readings recorded this

GSEA reactive oxygen species, change over time

no effect, p = 0.077

Reactive oxygen species | 42 | −1.14 | 0.302 | 1.32 | 0.077 | −1.63 3 | 0.014 3

PMID:30982861 · one of two readings recorded this

GSEA reactive oxygen species, change over time

decreases, p = 0.014

Reactive oxygen species | 42 | −1.14 | 0.302 | 1.32 | 0.077 | −1.63 3 | 0.014 3

PMID:30982861 · one of two readings recorded this

GSEA TNFA signaling via NFKB, change over time

increases

TNFA signaling via NFKB | 167 | 2.65 3 | 0 3 | 2.89 3 | 0 3 | −1.33 | 0.121

PMID:30982861 · one of two readings recorded this

GSEA TNFA signaling via NFKB, change over time

increases

TNFA signaling via NFKB | 167 | 2.65 3 | 0 3 | 2.89 3 | 0 3 | −1.33 | 0.121

PMID:30982861 · one of two readings recorded this

GSEA TNFA signaling via NFKB, change over time

no effect, p = 0.121

TNFA signaling via NFKB | 167 | 2.65 3 | 0 3 | 2.89 3 | 0 3 | −1.33 | 0.121

PMID:30982861 · one of two readings recorded this

GSEA xenobiotic metabolism, change over time

no effect, p = 0.356

Xenobiotic metabolism | 139 | −1.09 | 0.356 | 1.48 3 | 0.020 3 | −1.65 3 | 0.016 3

PMID:30982861 · one of two readings recorded this

GSEA xenobiotic metabolism, change over time

increases, p = 0.02

Xenobiotic metabolism | 139 | −1.09 | 0.356 | 1.48 3 | 0.020 3 | −1.65 3 | 0.016 3

PMID:30982861 · one of two readings recorded this

GSEA xenobiotic metabolism, change over time

decreases, p = 0.016

Xenobiotic metabolism | 139 | −1.09 | 0.356 | 1.48 3 | 0.020 3 | −1.65 3 | 0.016 3

PMID:30982861 · one of two readings recorded this

paired change over 12 months in prostate biopsy gene expression by RNA sequencing with Hallmark gene set enrichment, in men on active surveillance; secondary tissue metabolomics (Metabolon) and NRF2-target gene expression

no effect, no change in expression of any NRF2-regulated genes, FDR-adjusted P < 0.1

Not recorded as a finding: this platform holds no node for the endpoint

There was no evidence of a change in expression of any NRF2-regulated genes between the start and end of the dietary intervention (Benjamini–Hochberg FDR-adjusted P value <0.1).

PMID:30982861 · one of two readings recorded this

proportion of patients with increase in cancer grade over 12 mo

n = 48

Ten out of 48 patients (28%) exhibited an increase in their cancer grade over the 12 mo of the study

PMID:30982861 · one of two readings recorded this

PSA at 0 mo

PSA, µg/L 3 | 7.9 (5.9–12.0) | 7.6 (4.9–9.4) | 5.8 (4.4–8.7)

PMID:30982861 · one of two readings recorded this

PSA at 0 mo

PSA, µg/L 3 | 7.9 (5.9–12.0) | 7.6 (4.9–9.4) | 5.8 (4.4–8.7)

PMID:30982861 · one of two readings recorded this

PSA at 0 mo

PSA, µg/L 3 | 7.9 (5.9–12.0) | 7.6 (4.9–9.4) | 5.8 (4.4–8.7)

PMID:30982861 · one of two readings recorded this

PSA at 12 mo

PSA, µg/L 3 | 9.4 (6.6–10.4) | 7.3 (6.9–10.4) | 7.5 (5.6–9.3)

PMID:30982861 · one of two readings recorded this

PSA at 12 mo

PSA, µg/L 3 | 9.4 (6.6–10.4) | 7.3 (6.9–10.4) | 7.5 (5.6–9.3)

PMID:30982861 · one of two readings recorded this

PSA at 12 mo

PSA, µg/L 3 | 9.4 (6.6–10.4) | 7.3 (6.9–10.4) | 7.5 (5.6–9.3)

PMID:30982861 · one of two readings recorded this

tissue metabolites, paired change within each dietary arm

no effect

Paired analyses of metabolites from tissue biopsies did not identify any significant changes in metabolites within any of the 3 dietary intervention arms

PMID:30982861 · one of two readings recorded this

adverse events, total number and by type

no effect

Not recorded as a finding: Sentence names 'treatment group' not the compound, and counts rather than a proportion with at least one event; the supplement-adverse-event node needs a proportion.

There were no treatment group differences noted for each specific type of adverse event and the total number of adverse events (Table 2).

PMID:31155953 · one of two readings recorded this

AMACR mRNA, BSE vs placebo in cancer-positive men (RNA-seq)

decreases, p = 0.0001

AMACR mRNA levels were also significantly lower in biopsies of men that had cancer and took BSE supplements (P < 0.0001, compared to cancer positive placebo group)

PMID:31155953 · one of two readings recorded this

AMACR mRNA, cancer positive vs benign in placebo group (qPCR)

increases

among the placebo-treated subjects, a 6.3-fold difference in AMACR mRNA was found between cancer positive and benign groups

PMID:31155953 · one of two readings recorded this

AMACR mRNA overall BSE effect after log transformation (qPCR)

decreases, p = 0.0284

when the data were log transformed, a significant overall effect of BSE supplements was found on AMACR mRNA levels (P = 0.0284)

PMID:31155953 · one of two readings recorded this

AMACR mRNA, PCa vs benign in placebo group (RNA-seq)

increases, p = 0.0001

AMACR mRNA levels were significantly increased in patients with PCa from the placebo group in the RNA-seq dataset (P < 0.0001)

PMID:31155953 · one of two readings recorded this

ARLNC1 expression, cancer vs normal tissue in placebo group (RNA-seq)

increases, p = 0.0296

ARLNC1 was upregulated in prostate tissue from cancer patients from the placebo group in the RNA-seq dataset, as compared to normal tissue (P = 0.0296)

PMID:31155953 · one of two readings recorded this

ARLNC1 expression, interaction of PCa and BSE supplementation (RNA-seq)

decreases, p = 0.0281

a significant interaction between PCa and the effect of BSE supplementation was found (P = 0.0281)

PMID:31155953 · one of two readings recorded this

ARLNC1 level, BSE vs placebo in cancer-positive patients (qPCR)

decreases

A 4.3-fold lower level of ARLNC1 was found among samples from cancer-positive patient treated with BSE as compared to placebo

PMID:31155953 · one of two readings recorded this

ARLNC1 level, PCa vs no cancer in placebo group (qPCR)

increases

ARLNC1 levels were 4.5-fold higher in samples from PCa patients that received the placebo than samples from patients with no cancer

PMID:31155953 · one of two readings recorded this

difference in compliance between treatment groups

no effect, p = 0.44

There was no statistically significant difference in compliance between the treatment groups (P = 0.44)

PMID:31155953 · one of two readings recorded this

differentially expressed genes in prostate, cancer-by-BSE interaction

modulates, n = 40

identified 40 genes (27 up, 13 down) that were significantly altered due to BSE treatment

PMID:31155953 · one of two readings recorded this

PBMC HDAC activity, pre- to post-intervention change, pmol/min/mg protein

no effect

Not recorded as a finding: No outcome node for PBMC HDAC activity.

Overall, there were no statistically significant differences of pre- to postintervention changes between BSE and placebo groups (Supplemental Figure S1).

PMID:31155953 · one of two readings recorded this

PBMC HDAC activity, pre- to postintervention change, confirmed PCa subgroup

increases

within the subgroup of subjects with confirmed PCa diagnosis, BSE supplement significantly increased HDAC activity (Supplemental Figure S2)

PMID:31155953 · one of two readings recorded this

PBMC HDAC activity, pre- to postintervention change, overall

no effect

Overall, there were no statistically significant differences of pre- to postintervention changes between BSE and placebo groups (Supplemental Figure S1)

PMID:31155953 · one of two readings recorded this

PBMC histone deacetylase activity (pmol/min/mg protein); prostate biopsy IHC H-scores for H3K18ac, HDAC3, HDAC6, Ki-67 and p21; prostate RNA-seq gene expression, in men scheduled for prostate biopsy

no effect

Not recorded as a finding: this platform holds no node for the endpoint

Overall, there were no statistically significant differences of pre- to postintervention changes between BSE and placebo groups (Supplemental Figure S1).

PMID:31155953 · one of two readings recorded this

plasma SFN metabolites detected in placebo group

no effect

No SFN metabolites were detected in plasma from the placebo group

PMID:31155953 · one of two readings recorded this

plasma total SFN isothiocyanates and SFN-NAC, SFN-Cys, SFN-GSH, SFN-CG, pre- to postintervention change

increases

In plasma, pre- to postintervention changes in total SFN ITCs and individual SFN metabolites (SFN-NAC, SFN-Cys, SFN-GSH, and SFN-CG) were statistically significant in the BSE group

PMID:31155953 · one of two readings recorded this

proportion of subjects with compliance rate of at least 80%

no effect

84% of the subjects in the BSE group and 85% subjects in the placebo group had a compliance rate 80%

PMID:31155953 · one of two readings recorded this

prostate tissue IHC biomarkers H3K18ac, HDAC3, HDAC6, Ki-67, p21 (overall)

no effect

There was no statistically significant difference between treatment groups for all the examined tissue biomarkers

PMID:31155953 · one of two readings recorded this

prostate tissue IHC biomarkers, stratified by cancer and noncancer

no effect

Stratified by cancer and noncancer subgroup, no significant findings were found as well

PMID:31155953 · one of two readings recorded this

prostate tissue immunohistochemistry H-scores of H3K18ac, HDAC3, HDAC6, Ki-67 and p21, post-intervention biopsy

no effect

Not recorded as a finding: No outcome node for tissue IHC biomarkers.

There was no statistically significant difference between treatment groups for all the examined tissue biomarkers.

PMID:31155953 · one of two readings recorded this

subjects with prostate tissue analysed by IHC

n = 88

In this study, 88 (90%) subjects had prostate tissue analyzed by IHC

PMID:31155953 · one of two readings recorded this

urinary SFN-GSH and SFN-CG, pre- to postintervention change

no effect

SFN-GSH and SFN-CG changes in urine were greater in the BSE group but did not reach a significant level

PMID:31155953 · one of two readings recorded this

urinary total SFN metabolites and individual SFN, SFN-NAC, SFN-Cys, pre- to postintervention change

increases

Pre- to postintervention changes in total urinary SFN metabolites, and in individual SFN metabolites (SFN, SFN-NAC, and SFN-Cys), were statistically higher in the BSE versus the placebo group

PMID:31155953 · one of two readings recorded this

average enjoyment score

no effect

BT-S: Mean = 5.17 (SD = 1.03), BT-P: Mean = 5.17 (SD = 1.01), AT-S: Mean = 5.28 (SD = 1.26), and AT-P: Mean = 5.33 (SD = 1.08)

PMID:33503851 · one of two readings recorded this

average number of training days

no effect

maximum = 84 days: BT-S: Mean = 83.56 (SD = 0.65), BT-P: Mean = 83.22 (SD = 1.14), AT-S: Mean = 83.76 (SD = 1.33), and AT-P: Mean = 83.17 (SD = 1.47)

PMID:33503851 · one of two readings recorded this

cognitive performance and emotional state, cognitive training by nutrition interaction and other main effects

no effect

we did not find any significant main effects or interaction effects of cognitive training or nutrition on cognitive performance or emotional state (Table 4)

PMID:33503851 · one of two readings recorded this

correlation between improved cognitive function and urinary SFN-NAC

no effect

We found no significant correlation between improved cognitive function and urinary SFN-NAC

PMID:33503851 · one of two readings recorded this

number of supplement-intake days

no effect

maximum = 84 days: BT-S: Mean = 83.31 (SD = 2.08), BT-P: Mean = 82.03 (SD = 1.64), AT-S: Mean = 82.79 (SD = 1.81), and AT-P: Mean = 82.56 (SD = 1.78)

PMID:33503851 · one of two readings recorded this

processing speed (digit symbol coding, Cd), main effect of cognitive training

increases, p = 0.05

a significant main effect of cognitive training on processing speed performance (SS: F (1, 135) = 7.054, η2 = 0.06, adjusted p < 0.05, Cd: F (1, 135) = 7.743, η2 = 0.07, adjusted p < 0.05)

PMID:33503851 · one of two readings recorded this

processing speed, symbol search and digit symbol coding (WAIS-III)

increases

Not recorded as a finding: No outcome node for processing speed on WAIS-III subtests.

Finally, the SFN intake group demonstrated improvements in processing speed and working memory performance compared to the placebo intake group.

PMID:33503851 · both readings recorded this

processing speed (symbol search, SS), main effect of cognitive training

increases, p = 0.05

a significant main effect of cognitive training on processing speed performance (SS: F (1, 135) = 7.054, η2 = 0.06, adjusted p < 0.05, Cd: F (1, 135) = 7.743, η2 = 0.07, adjusted p < 0.05)

PMID:33503851 · one of two readings recorded this

processing speed (symbol search, SS), main effect of nutrition

increases, p = 0.05

a significant main effect of nutrition on processing speed (SS: F (1, 135) = 9.05, η2 = 0.08, adjusted p < 0.05) and working memory (BS: F (1, 135) = 8.44, η2 = 0.07, adjusted p < 0.05) performances

PMID:33503851 · one of two readings recorded this

satisfaction score

no effect

BT-S: Mean = 4.03 (SD = 1.42), BT-P: Mean = 4.17 (SD = 1.33), AT-S: Mean = 3.88 (SD = 1.29), and AT-P: Mean = 4.33 (SD = 1.20)

PMID:33503851 · one of two readings recorded this

urinary SFN-NAC, SFN vs placebo intake group

increases, p = 0.008

urinary SFN-NAC was confirmed to be significantly higher in the SFN intake group (Mean = 4.2, SD = 6.1) than in the placebo intake group (Mean = 1.8, SD = 4.1; t (140) = 2.71, p = 0.008, d = 0.45)

PMID:33503851 · one of two readings recorded this

working memory (digit span backward, BS), main effect of nutrition

increases, p = 0.05

a significant main effect of nutrition on processing speed (SS: F (1, 135) = 9.05, η2 = 0.08, adjusted p < 0.05) and working memory (BS: F (1, 135) = 8.44, η2 = 0.07, adjusted p < 0.05) performances

PMID:33503851 · one of two readings recorded this

ABC rating by length of SF exposure vs pre-treatment baseline (non-randomized)

decreases, p = 0.001

Ratings on the ABC and SRS-2 improved with a non-randomized analysis of the length of exposure to SF, compared to the pre-treatment baseline (p < 0.001)

PMID:34034808 · one of two readings recorded this

Aberrant Behavior Checklist (caregiver rating), SF vs PL

decreases

Cohen's d - 0.96; 95% CI - 1.73, - 0.15

PMID:34034808 · one of two readings recorded this

biomarkers of glutathione redox status, mitochondrial respiration, inflammatory markers and heat shock proteins

modulates

There were significant changes with SF compared to PL in biomarkers of glutathione redox status, mitochondrial respiration, inflammatory markers and heat shock proteins

PMID:34034808 · one of two readings recorded this

OACIS general level of autism, SF vs PL

no effect

Cohen's d 0.21; 95% CI - 0.46, 0.88 and 0.10; 95% CI - 0.52, 0.72, respectively

PMID:34034808 · one of two readings recorded this

OACIS general level of autism, SF vs PL

no effect

Cohen's d 0.21; 95% CI - 0.46, 0.88 and 0.10; 95% CI - 0.52, 0.72, respectively

PMID:34034808 · one of two readings recorded this

Ohio Autism Clinical Impressions Scale (OACIS) general level of autism, primary outcome; Aberrant Behavior Checklist and Social Responsiveness Scale-2 caregiver ratings, secondary, in children aged 3-12 with ASD

no effect

Not recorded as a finding: this platform holds no node for the endpoint

Treatment effects on the primary outcome measure, the Ohio Autism Clinical Impressions Scale (OACIS), in the general level of autism were not significant between SF and PL groups at 7 and 15 weeks.

PMID:34034808 · one of two readings recorded this

Ohio Autism Clinical Impressions Scale (OACIS) general level of autism, primary outcome; also Aberrant Behavior Checklist and Social Responsiveness Scale-2

no effect

Not recorded as a finding: this platform holds no node for the endpoint

Treatment effects on the primary outcome measure, the Ohio Autism Clinical Impressions Scale (OACIS), in the general level of autism were not significant between SF and PL groups at 7 and 15 weeks.

PMID:34034808 · one of two readings recorded this

Social Responsiveness Scale-2 (caregiver rating), SF vs PL

no effect

Caregiver ratings on secondary outcome measures improved significantly on the Aberrant Behavior Checklist (ABC) at 15 weeks (Cohen's d - 0.96; 95% CI - 1.73, - 0.15), but not on the Social Responsiveness Scale-2 (SRS-2)

PMID:34034808 · one of two readings recorded this

SRS-2 rating by length of SF exposure vs pre-treatment baseline (non-randomized)

decreases, p = 0.001

Ratings on the ABC and SRS-2 improved with a non-randomized analysis of the length of exposure to SF, compared to the pre-treatment baseline (p < 0.001)

PMID:34034808 · one of two readings recorded this

alliin and alliin-derived metabolite concentrations in prostate tissue

no effect

there was no significant difference in the concentrations of these compounds in the prostate of men consuming supplements derived from garlic compared to men not consuming these supplements

PMID:36014767 · one of two readings recorded this

sulforaphane level in prostate tissue (transition and peripheral zone)

increases, p = 0.0001

Sulforaphane occurred in significantly higher levels in the prostate tissue (both within the transition and peripheral zone) of men consuming the glucoraphanin containing supplements (p < 0.0001)

PMID:36014767 · one of two readings recorded this

ABC total raw score between-group difference

no effect, p = 0.2742

ABC: 0 weeks p = 0.2742, 18 weeks p = 0.4352, and 36 weeks 0.576

PMID:36771424 · one of two readings recorded this

ABC total raw score between-group difference

no effect, p = 0.4352

ABC: 0 weeks p = 0.2742, 18 weeks p = 0.4352, and 36 weeks 0.576

PMID:36771424 · one of two readings recorded this

ABC total raw score between-group difference

no effect, p = 0.576

ABC: 0 weeks p = 0.2742, 18 weeks p = 0.4352, and 36 weeks 0.576

PMID:36771424 · one of two readings recorded this

Aberrant Behaviour Checklist total score, Social Responsiveness Scale-2 total raw score, and ADOS-2 subscale scores in children with autism aged 3-7 years

Not recorded as a finding: this platform holds no node for the endpoint

We found no significant clinical improvement in the behavioural outcome measures evaluated in children with ASD aged 3-7 years that were treated with sulforaphane.

PMID:36771424 · one of two readings recorded this

ADOS-2 subscale scores between-group difference

no effect, p = 0.8782

ADOS-2: 0 weeks p = 0.8782, 18 weeks p = 0.4788, and 36 weeks 0.9414

PMID:36771424 · one of two readings recorded this

ADOS-2 subscale scores between-group difference

no effect, p = 0.4788

ADOS-2: 0 weeks p = 0.8782, 18 weeks p = 0.4788, and 36 weeks 0.9414

PMID:36771424 · one of two readings recorded this

ADOS-2 subscale scores between-group difference

no effect, p = 0.9414

ADOS-2: 0 weeks p = 0.8782, 18 weeks p = 0.4788, and 36 weeks 0.9414

PMID:36771424 · one of two readings recorded this

SRS-2 total raw score between-group difference

no effect, p = 0.5235

SRS-2: 0 weeks p = 0.5235, 18 weeks p = 0.9176, and 36 weeks 0.7435

PMID:36771424 · one of two readings recorded this

SRS-2 total raw score between-group difference

no effect, p = 0.9176

SRS-2: 0 weeks p = 0.5235, 18 weeks p = 0.9176, and 36 weeks 0.7435

PMID:36771424 · one of two readings recorded this

SRS-2 total raw score between-group difference

no effect, p = 0.7435

SRS-2: 0 weeks p = 0.5235, 18 weeks p = 0.9176, and 36 weeks 0.7435

PMID:36771424 · one of two readings recorded this

Cmax of the sum of sulforaphane and metabolites (total thiol) in blood, and urinary excretion of sulforaphane and metabolites, after SFX-01 enteric-coated tablets for 7 days

Cmax 0.43 to 2.12 umol/L in 3-6 h across cohorts

Not recorded as a finding: this platform holds no node for the endpoint

The observed peak blood concentration (Cmax) for the sum of SFN and metabolites (total thiol) across all treatment cohorts ranged from 0.43 to 2.12 µmol/L in 3-6 h.

PMID:39520658 · one of two readings recorded this

peak blood concentration (Cmax) of the sum of sulforaphane and metabolites (total thiol) after SFX-01 enteric-coated tablets

ranged from 0.43 to 2.12 umol/L in 3-6 h

Not recorded as a finding: this platform holds no node for the endpoint

The observed peak blood concentration (Cmax) for the sum of SFN and metabolites (total thiol) across all treatment cohorts ranged from 0.43 to 2.12 µmol/L in 3-6 h.

PMID:39520658 · one of two readings recorded this

treatment-emergent adverse events

unclear

Treatment-emergent adverse events (TEAEs) occurred in 94% of participants who received SFX-01

PMID:39520658 · one of two readings recorded this

urinary excretion of SFN and metabolites by dose

no effect

the proportion excreted did not appear to be influenced by the dose

PMID:39520658 · one of two readings recorded this

bronchial histopathology scores

no effect

Supplementation of sulforaphane did not show significant impact on bronchial histopathology

PMID:40041932 · one of two readings recorded this

caspase-3 index in bronchial biopsies

no effect

Sulforaphane treatment had no impact on the caspase-3 or TUNEL index in bronchial biopsies

PMID:40041932 · one of two readings recorded this

high-density (3+) positive Ki-67 (post vs pretreatment change)

decreases, p = 0.004, n = 37

with a 44% decrease in the sulforaphane group compared with a 71% increase in the placebo (P = 0.004)

PMID:40041932 · one of two readings recorded this

Ki-67 index in bronchial biopsies (post vs pretreatment change)

decreases, p = 0.014, n = 37

significantly reduced the Ki-67 index with a 20% decrease in the sulforaphane group and a 65% increase in the placebo (P = 0.014)

PMID:40041932 · one of two readings recorded this

Ki-67 index reduction by sulforaphane bioavailability

decreases, p = 0.019

Higher bioavailability of sulforaphane was correlated with greater reduction of the Ki-67 index (P for trend = 0.019)

PMID:40041932 · one of two readings recorded this

Ki-67 proliferation index in bronchial biopsies, post- versus pretreatment change

decreases, 20% decrease in the sulforaphane group and a 65% increase in the placebo, p = 0.014

Not recorded as a finding: this platform holds no node for the endpoint

Supplementation of sulforaphane did not show significant impact on bronchial histopathology but significantly reduced the Ki-67 index with a 20% decrease in the sulforaphane group and a 65% increase in the placebo (P = 0.014).

PMID:40041932 · one of two readings recorded this

Ki-67 proliferation index in bronchial biopsies, post- versus pretreatment, in former smokers

decreases, 20% decrease in the sulforaphane group versus 65% increase in placebo, p = 0.014, n = 37

Not recorded as a finding: this platform holds no node for the endpoint

Supplementation of sulforaphane did not show significant impact on bronchial histopathology but significantly reduced the Ki-67 index with a 20% decrease in the sulforaphane group and a 65% increase in the placebo (P = 0.014).

PMID:40041932 · one of two readings recorded this

TUNEL index in bronchial biopsies

no effect

Sulforaphane treatment had no impact on the caspase-3 or TUNEL index in bronchial biopsies

PMID:40041932 · one of two readings recorded this

triglycerides

decreases

Sulforaphane led to significant reductions in metabolic markers, including LDL, triglycerides, and cholesterol

PMID:41184790 · one of two readings recorded this

cholesterol

decreases

Sulforaphane led to significant reductions in metabolic markers, including LDL, triglycerides, and cholesterol

PMID:41184790 · one of two readings recorded this

cognitive measures

no effect

No cognitive benefits were observed

PMID:41184790 · one of two readings recorded this

discontinuation rate

decreases, p = 0.02

Discontinuation rates were lower in the sulforaphane group (RR = 0.68; 95% CI: 0.49 to 0.95; p = 0.02)

PMID:41184790 · one of two readings recorded this

LDL cholesterol and total cholesterol, pooled

decreases

Not recorded as a finding: Same sentence; LDL derivation unstated and 'cholesterol' not clearly total cholesterol, so mapping to ldl-cholesterol / total-cholesterol nodes not safe from abstract.

Sulforaphane led to significant reductions in metabolic markers, including LDL, triglycerides, and cholesterol.

PMID:41184790 · one of two readings recorded this

LDL

decreases

Sulforaphane led to significant reductions in metabolic markers, including LDL, triglycerides, and cholesterol

PMID:41184790 · one of two readings recorded this

PANSS general psychopathology score

decreases, p = 0.02

General psychopathology scores improved significantly (MD= -1.5; 95% CI: -2.78 to -0.23; p = 0.02)

PMID:41184790 · one of two readings recorded this

PANSS negative symptom score

decreases, p = 0.02

a modest improvement in negative symptoms was found at 12 week- time point (MD= -1.06; 95% CI: -1.95 to -0.16; p = 0.02)

PMID:41184790 · one of two readings recorded this

PANSS positive symptom score

no effect

Sulforaphane did not significantly improve PANSS total or positive symptom scores at the latest follow-up (ranging from 24 weeks to 18 weeks) or at a consistent 12-week time point

PMID:41184790 · one of two readings recorded this

PANSS positive symptom score

no effect

Sulforaphane did not significantly improve PANSS total or positive symptom scores at the latest follow-up (ranging from 24 weeks to 18 weeks) or at a consistent 12-week time point

PMID:41184790 · one of two readings recorded this

PANSS total and positive symptom scores at latest follow-up

no effect

Not recorded as a finding: No PANSS outcome node.

Sulforaphane did not significantly improve PANSS total or positive symptom scores at the latest follow-up (ranging from 24 weeks to 18 weeks) or at a consistent 12-week time point.

PMID:41184790 · one of two readings recorded this

PANSS total score

no effect

Sulforaphane did not significantly improve PANSS total or positive symptom scores at the latest follow-up (ranging from 24 weeks to 18 weeks) or at a consistent 12-week time point

PMID:41184790 · one of two readings recorded this

PANSS total score

no effect

Sulforaphane did not significantly improve PANSS total or positive symptom scores at the latest follow-up (ranging from 24 weeks to 18 weeks) or at a consistent 12-week time point

PMID:41184790 · one of two readings recorded this

total cholesterol (named only as 'cholesterol')

decreases

Not recorded as a finding: The sentence says only 'cholesterol'; whether total cholesterol is meant is not stated, so not mapped to total-cholesterol.

Sulforaphane led to significant reductions in metabolic markers, including LDL, triglycerides, and cholesterol.

PMID:41184790 · one of two readings recorded this

docking binding energy of sulforaphane with top 10 core targets

unclear

The binding energies between sulforaphane and the top 10 core targets are all ≤ -4.0 kcal/mol

PMID:41275316 · one of two readings recorded this

incidence of adverse events

no effect

No significant difference was observed in the incidence of adverse events

PMID:41275316 · one of two readings recorded this

Social Responsiveness Scale score in autism spectrum disorder, pooled across trials

decreases

Not recorded as a finding: this platform holds no node for the endpoint

Pooled results demonstrated that both 4-5 weeks and 8-10 weeks of sulforaphane supplementation significantly decreased the scores on the Social Responsiveness Scale compared to placebo controls.

PMID:41275316 · one of two readings recorded this

Social Responsiveness Scale score in autism spectrum disorder, pooled meta-analysis vs placebo

decreases

Not recorded as a finding: this platform holds no node for the endpoint

Pooled results demonstrated that both 4-5 weeks and 8-10 weeks of sulforaphane supplementation significantly decreased the scores on the Social Responsiveness Scale compared to placebo controls.

PMID:41275316 · one of two readings recorded this

Social Responsiveness Scale score

decreases

Pooled results demonstrated that both 4-5 weeks and 8-10 weeks of sulforaphane supplementation significantly decreased the scores on the Social Responsiveness Scale compared to placebo controls

PMID:41275316 · one of two readings recorded this

Social Responsiveness Scale score

decreases

Pooled results demonstrated that both 4-5 weeks and 8-10 weeks of sulforaphane supplementation significantly decreased the scores on the Social Responsiveness Scale compared to placebo controls

PMID:41275316 · one of two readings recorded this

STAT1 level and ASD risk (Mendelian randomization)

decreases

Mendelian randomization further revealed an inverse association between STAT1 levels and ASD risk

PMID:41275316 · one of two readings recorded this

conversion efficiency of glucoraphanin to sulforaphane plus metabolites, urinary 24 h recovery by LC-MS as percent of GR dose

increases, n = 16

Not recorded as a finding: subject_absent

The combination of BSE and mustard seed powder containing active Myr (GR + Myr), on average, doubled bioavailability of GR to SF and SF metabolites as a percent of the 115 µmol (50 mg) GR dose

PMID:41692762 · one of two readings recorded this

conversion of glucoraphanin to sulforaphane plus metabolites in 24 h urine

increases, p = 0.0016, n = 16

from 18.6 ± 3.1% (range 2.2–38.1%) without myrosinase to 39.8 ± 3.1% (range 5.3–76.9%) with exogenous Myr from mustard seed (11.30, df = 1, 43, p = 0.0016)

PMID:41692762 · one of two readings recorded this

conversion of glucoraphanin to sulforaphane plus metabolites in 8 to 24 h urine

unclear, p = 0.0037

11.7 ± 1.3% for GR + Myr vs. 8.9 ± 1.3% for GR alone (F = 9.45, df = 1, 43, p = 0.0037)

PMID:41692762 · one of two readings recorded this

conversion of glucoraphanin to sulforaphane plus metabolites in first 8 h urine

increases, p = 0.0005

in the first 8 h urine collection (Time 8 h), which was significantly higher in the GR + Myr treatment compared to GR alone: 25.4 ± 2.7% vs. 8.0 ± 2.7% (F = 20.60, df = 1, 14, p = 0.0005)

PMID:41692762 · one of two readings recorded this

correlation of B. theta 2158 copy number with GR conversion

increases, p = 0.00322

B. theta 2158 (linear model, F = 3.548, adjusted r2 = 0.4358, p = 0.00322)

PMID:41692762 · one of two readings recorded this

correlation of B. theta 2159 copy number with GR conversion

increases, p = 0.0155

B. theta 2159 (linear model, F = 2.756, adjusted r2 = 0.3054, p = 0.0155)

PMID:41692762 · one of two readings recorded this

correlation of BT2156 copy number with GR conversion

increases, p = 0.0138

BT2156 (lm, F = 3.439, adjusted r2 = 0.6073, p = 0.0138)

PMID:41692762 · one of two readings recorded this

correlation of BT2157 copy number with GR conversion

increases, p = 0.0119

BT2157 (lm, F = 3.562, adjusted r2 = 0.6254, p = 0.0119)

PMID:41692762 · one of two readings recorded this

correlation of BT2158 copy number with GR conversion

increases, p = 0.00725

BT2158 (lm, F = 3.984, adjusted r2 = 0.68, p = 0.00725)

PMID:41692762 · one of two readings recorded this

correlation of BT2159 copy number with GR conversion

increases, p = 0.0352

BT2159 (lm, F = 2.708, adjusted r2 = 0.475, p = 0.0352)

PMID:41692762 · one of two readings recorded this

fecal bacterial community similarity by supplementation order (Jaccard, permanova)

no effect, p = 0.6989

Figure S5, GR + Myr first vs. GR first, permanova test p = 0.6989

PMID:41692762 · one of two readings recorded this

GR conversion percentage after GR alone by treatment order

increases, p = 0.033

had significantly higher GR conversion percentages following either GR + Myr or GR alone (p = 0.0089 and p = 0.033, respectively; two-tailed unpaired t-test of unequal variance)

PMID:41692762 · one of two readings recorded this

GR conversion percentage after GR + Myr by treatment order

increases, p = 0.0089

had significantly higher GR conversion percentages following either GR + Myr or GR alone (p = 0.0089 and p = 0.033, respectively; two-tailed unpaired t-test of unequal variance)

PMID:41692762 · one of two readings recorded this

total SF conversion, gender by treatment interaction

unclear, p = 0.0796

Gender by Treatment interaction, F = 3.57, df = 1, 14, p = 0.0796

PMID:41692762 · one of two readings recorded this

total SF conversion, gender effect

modulates, p = 0.0326

for Gender, F = 5.62, df = 1, 14, p = 0.0326

PMID:41692762 · one of two readings recorded this

total SF conversion, treatment effect in split-plot model

increases, p = 0.0004

for Treatment (as expected), F = 21.40, df = 1,14, p = 0.0004

PMID:41692762 · one of two readings recorded this